Suggested remit: To appraise the clinical and cost effectiveness of 177Lu-PSMA-617 within its marketing authorisation for treating prostate-specific membrane antigen (PSMA) positive, hormone-relapsed metastatic prostate cancer previously treated with androgen receptor directed therapy (ARDT) and taxane based chemotherapy.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
TA
|
| ID number |
3840
|
Provisional Schedule
| Expected publication |
15 November 2023 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors |
Novartis Pharmaceuticals |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Govenment |
| Patient carer groups |
Prostate Cancer UK |
| |
Tackle prostate cancer |
| Professional groups |
Association of Cancer Physicians |
| |
British Nuclear Medicine Society |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Bayer |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
06 September 2023
|
Committee meeting: 3 |
|
09 August 2023
|
The appraisal committee meeting scheduled for 2 August 2023 is now expected to take place on 6 September 2023. |
|
21 February 2023 - 14 March 2023
|
Draft guidance: 2 |
|
12 January 2023
|
Committee meeting: 2 |
|
12 October 2022 - 02 November 2022
|
Draft guidance |
|
04 February 2022
|
The timelines for this appraisal have been amended. The appraisal committee meeting is now scheduled to take place on Thursday 15 September 2022. |
|
03 November 2021
|
Invitation to participate |
|
16 July 2021
|
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
For information, we anticipate that the appraisal will now begin during early November 2021. |
|
08 June 2021 - 06 July 2021
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
01 September 2020
|
In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual